Losartan, a therapeutic candidate in congenital muscular dystrophy: Studies in the dy2J/dy2J Mouse

Losartan Decreases Cardiac Muscle Fibrosis and Improves Cardiac Function in Dystrophin-Deficient Mdx Mice

(2011) Christopher F. Spurney et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

p38 kinase inhibitor approved for idiopathic pulmonary fibrosis

(2011) Nuala Moran   NATURE BIOTECHNOLOGY

The Ras Antagonist, Farnesylthiosalicylic Acid (FTS), Decreases Fibrosis and Improves Muscle Strength in dy2J/dy2J Mouse Model of Muscular Dystrophy

(2011) Yoram Nevo et al.   PLoS One

Noncanonical TGF  Signaling Contributes to Aortic Aneurysm Progression in Marfan Syndrome Mice

(2011) T. M. Holm et al.   SCIENCE

Angiotensin II Type 2 Receptor Signaling Attenuates Aortic Aneurysm in Mice Through ERK Antagonism

(2011) J. P. Habashi et al.   SCIENCE

Losartan Restores Skeletal Muscle Remodeling and Protects Against Disuse Atrophy in Sarcopenia

(2011) T. N. Burks et al.   Science Translational Medicine

Atrial Fibrillation Induces Myocardial Fibrosis Through Angiotensin II Type 1 Receptor–Specific Arkadia-Mediated Downregulation of Smad7

(2010) Xuyu He et al.   CIRCULATION RESEARCH

Fibrosis inhibition and muscle histopathology improvement in laminin-α2-deficient mice

(2010) Yoram Nevo et al.   MUSCLE & NERVE

Improved muscle strength and mobility in the dy2J/dy2J mouse with merosin deficient congenital muscular dystrophy treated with Glatiramer acetate

(2010) Oshrat Dadush et al.   NEUROMUSCULAR DISORDERS

Angiotensin II increases collagen I expression via transforming growth factor-beta1 and extracellular signal-regulated kinase in cardiac fibroblasts

(2009) Xiuren Gao et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Intramuscular renin–angiotensin system is activated in human muscular dystrophy

(2009) Guilian Sun et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Animal Models for Genetic Neuromuscular Diseases

(2008) Mariz Vainzof et al.   JOURNAL OF MOLECULAR NEUROSCIENCE